HanchorBio Strengthens Global Positions with TPEx Listing
HanchorBio Inc. has taken a monumental step in its journey by officially listing on the Taipei Exchange (TPEx) under the ticker symbol 7827.TWO. This move was announced on July 16, 2025, marking a significant milestone as the company embarks on its mission to reshape cancer treatment through its innovative immunotherapy, HCB101.
Founded with the vision to be a leader in immunotherapy biologics, HanchorBio’s successful IPO reflects its commitment to developing next-generation cancer treatments. The listing on TPEx comes with over USD 80 million in equity financing, backed by reputable institutional investors, signaling strong market confidence in the company's prospects.
A Bold Vision for Cancer Treatment
Scott Liu, Co-Founder and CEO of HanchorBio, reflected on this achievement, saying, "This IPO signifies more than just a financial milestone — it is a defining moment for all of us at HanchorBio." He highlighted the company's journey over recent years, which aimed to create impactful immunotherapies. HCB101, a best-in-class CD47-targeting immunotherapy, is at the forefront of this ambition. The successful listing positions the company strategically in a booming market, as the CD47 immunotherapy sector is projected to exceed US$40 billion by 2035.
HanchorBio's dedication does not only lie in its flagship therapy but also in its innovative platform — FBDB™ — which has considerable potential for licensing and development. The company operates actively across multiple regions, including the U.S. and mainland China, further solidifying its global presence.
Promising Clinical Trials and Results
HCB101 has been gathering momentum, particularly since the launch of Phase 2 clinical trials in March 2025. The trials have involved participants from various regions, including Taiwan, the United States, and China. Interim results shared during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting showcased promising outcomes, including:
- - Safety and Tolerability: The trials exhibited favorable safety profiles amid various dose cohorts.
- - Clinical Indicators: Notable indicators such as high-level CD47 receptor occupancy in immune cells.
- - Anti-Tumor Activity: Early signs of anti-tumor activity were reported, marking significant progress in treatment effectiveness.
Among the trial's highlights, six patients in lower dose groups showcased stable disease outcomes, including an ovarian cancer patient who sustained disease control for over 32 weeks. Patients in higher dose cohorts reported confirmed partial responses and impressive tumor reductions, illustrating the potential efficacy of HCB101.
Taiwan's Role in Biotech Innovation
This IPO underscores the expanding role of Taiwan as a formidable hub for biotechnological innovation. The collaboration between the government and industry, which nurtures emerging biotech firms, contributes to a thriving ecosystem that aids in breakthroughs in medical treatments. HanchorBio believes it can help cultivate the next generation of pioneering companies within this landscape.
In addition to having a validated clinical asset, investors seeking to support HanchorBio will gain exposure to a seasoned leadership team adept in navigating the complexities of the biotech industry, demonstrated by their track record over 30 IND submissions and numerous NDA/BLA filings.
The Future of Immunotherapy
HanchorBio is committed to advancing its clinical trials while exploring further opportunities within the global market for innovative immunotherapies. The company aims to remain at the forefront of immuno-oncology, with the objective of bringing impactful therapies like HCB101 to patients worldwide.
Based in Taipei, Shanghai, and San Francisco, HanchorBio’s mission is not just confined to making profits but extends to fostering a long-lasting impact in the realm of cancer treatment — reactivating the immune system against cancerous diseases. With its recent successes, HanchorBio undoubtedly strengthens its stance as a leader in the global biotechnology sector.
For further details about HanchorBio and its offerings, please visit their
official website or follow them on their LinkedIn page.